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Background. Theophylline was shown to induce contracture development in porcine malignant hyperthermia (MH) susceptible
(MHS) skeletal muscles in vitro. The purpose of the current study was to investigate the in vivo eﬀects of theophylline in
MHS and MH normal (MHN) swine. Methods. MH-trigger-free general anesthesia was performed in MHS and MHN swine.
Theophylline was administered intravenously in cumulative doses up to 93.5mg·kg−1. The clinical occurrence of MH was
deﬁned by changes of central-venous pCO2, central-venous pH, and body core temperature. Results. Theophylline induced
comparable clinical alterations in the anesthetized MHS and MHN swine, especially in regard to hemodynamic data. No pig
developed hypermetabolism and/or MH according to deﬁned criteria. All animals died with tachycardia followed by ventricular
ﬁbrillation.Conclusions. Thecumulative theophylline doses usedin this studywere much higher than doses usedtherapeutically in
humans, as demonstrated by measured blood concentrations. Theophylline is thus not a trigger of MH in genetically determined
swine.
1.Introduction
Malignant hyperthermia (MH) is an autosomally inherited,
potentially lethal myopathy with a heterogeneous etiology
that is usually triggered by volatile anesthetics and depo-
larizing muscle relaxants [1]. It is widely accepted that
susceptibilitytoMHiscausedbyabnormalCa2+ metabolism
within the skeletal-muscle ﬁber. The site of the defect in
MH appears to lie in the Ca2+ release mechanism of the
sarcoplasmic reticulum (SR) in skeletal muscle, namely, in
the complex of the dihydropyridine (DHPR) and ryanodine
receptors (RyR).
Ca2+ homeostasisinskeletalmuscleisregulatedbyavari-
ety of intracellular second-messenger systems. Alterations
in some second-messenger systems have been found to be
associated with MH [2, 3]; the cyclic AMP (cAMP) system
alsoseemstobeaﬀectedinMH.Inskeletal-musclecellsfrom
MH-susceptible (MHS) patients and animals, higher cAMP
levels were measured compared to normal (MHN) subjects
[4–7].
The mode of action of methylxanthines such as caﬀeine
and theophylline is concentration dependent [8]. While
they act by adenosine-receptor antagonism at lower concen-
trations, at higher concentrations they are also unspeciﬁc
phosphodiesterase(PDE)inhibitors.PDEinhibitorsproduce
a receptor-independent increase in Ca2+ release from the
SR via the RyR in cardiac muscle by decreasing the rate of
cAMPdegradation.Thiseﬀectcouldalsobedemonstratedin
skeletal muscle as an increase in isometric contraction after
application of PDE inhibitors [9, 10].
Theophylline (1,3-dimethylxanthine) was shown to
induce contracture development in porcine skeletal mus-
cle in vitro [11]. Furthermore, clear diﬀerences could be
demonstratedbetweenMHNandMHSmuscle:MHSmuscle
developed signiﬁcantly greater contractures compared to
MHN specimens after bolus administration of 3mmol·L−1
or 5mmol·L−1 theophylline. These results were comparable
with in vitro contracture tests (IVCTs) with caﬀeine and
could be explained by the chemical analogies of both
substances. In contrast to caﬀeine, however, theophylline is
a widely used pharmaceutical substance. The purpose of
the current study was to investigate the in vivo eﬀects of
theophylline in MHS and MHN swine.2 Journal of Biomedicine and Biotechnology
2. Methods
After approval by the animal research committee of the
University Hospital Hamburg-Eppendorf, 6 MHN German
Landrace pigs weighing 39–48kg, aged 3–5 months, and 6
MHS Pietrain pigs weighing 26–33kg, aged 3–5 months,
from a special breeding farm (Research Station Thalhausen,
Technical University Munich, Germany) were investigated.
Prior to the study, in all animals genomic DNA was isolated
from blood preserved in ethylenediaminetetraacetic acid to
check for the presence of the Arg615-Cys point mutation on
chromosome 6, indicating MH susceptibility [12].
Swine were fasted overnight with free access to water.
General anesthesia was induced by administration of
ketamine10mg·kg−1 intramuscularly(Ketavet,Pharmacia&
Upjohn, Erlangen, Germany). After insertion of a venous
cannula into an ear vein, anesthesia was deepened with
propofol 10mg·kg−1 (Diprivan 2%, Astra-Zeneca, Plank-
stadt, Germany) and fentanyl 10μg·kg−1 (Fentanyl-Janssen,
Janssen-Cilag, Neuss, Germany) intravenously (i.v.). After
tracheotomy and intubation, the lungs were mechanically
ventilated with an air/oxygen mixture (fraction of inspired
oxygen (FiO2) 0.4). Anesthesia was maintained with propo-
fol 10mg·kg−1·h−1 and fentanyl 50μg·kg−1·h−1.N e u r o -
muscular blocking drugs were not administered. A multilu-
men central-venous line was inserted into the right internal-
jugular vein. One lumen was used for withdrawal of blood
samplesandmeasurementofcentral-venouspressure(CVP),
the second for administration of theophylline and ﬂuid infu-
sion (5–10mL·kg−1·h−1 Ringer’s solution), and the third
for administration of anesthetics. Cannulas were inserted
into both femoral arteries: one was used for withdrawal of
blood samples, the other for continuous measurement of
arterialpressureandbodycoretemperature(PiCCO,Pulsion
Medical Systems, Munich, Germany). Normothermia was
maintained by forced-air warming, and rectal and intravas-
cular body temperatures were measured continuously.
A blood-gas analyzer (ABL625, Radiometer, Copen-
hagen, Denmark) was used for monitoring arterial and
venous oxygen saturation, oxygen partial pressure (pO2),
carbon dioxide partial pressure (pCO2), pH, and potassium
and lactate levels. Mechanical ventilation was adjusted to
maintain venous pCO2 at 46 ± 4mmHg; the body core tem-
perature was adjusted to 37.5 ± 0.2◦C before the experiment
was started. Once a steady state was achieved for at least 30
minutes, baseline values were recorded for all variables.
Theophylline (Bronchoparat, Klinge Pharma, Munich,
Germany) 1.0mg·kg−1 was administered as an i.v. bolus.
Subsequent doses were given every 10 minutes to reach cu-
mulative doses of 3.5, 8.5, 18.5, 33.5, 53.5, and 93.5mg·kg−1.
The clinical occurrence of MH was deﬁned by the
development of two of three conditions: central-venous
pCO2 ≥75mmHg, central-venous pH ≤ 7.20, and an
increase of intravascular body core temperature by ≥2.0◦C
as measured using the PiCCO system.
During the experiments, hemodynamic variables (heart
rate (HR), mean arterial pressure (MAP), CVP, cardiac
output), end-tidal CO2 concentration (etCO2), rectal and
intravascular body temperature (◦C), blood-gas concentra-
tions (O2 saturation (SaO2), pCO2, pH), and lactate levels
were measured every 5 minutes. Every 10 minutes, blood
samples were taken for gas-chromatographic measurement
of theophylline concentrations. After all experiments were
completed, the pigs were killed using 10% magnesium
chloride solution i.v.
Statistical evaluation was performed using a computer-
based program (StatView 4.57, Abacus Concepts, Berkeley,
CA). All data are presented as median and range. Inter-
group variations were calculated with the Mann-Whitney
test; intragroup diﬀerences were calculated with analysis
of variance for repeated measures. If appropriate, subse-
quent comparisons were performed using Scheﬀ´ e’s posthoc
method. Results were considered signiﬁcant if P values were
less than 0.05.
3. Results
Theophylline induced comparable clinical alterations in the
anesthetized MHS and MHN swine, especially in regard to
hemodynamic data. However, signiﬁcant diﬀerences could
not be found between MHS and MHN swine. Moreover,
no pig developed hypermetabolism and/or MH according to
the deﬁned criteria. Furthermore, clinical signs of muscular
alterations, for example, general muscle rigidity, were not
observed in any swine. After cumulative administration
of 93.5mg·kg−1, all animals died with tachycardia and
hypotension followed by ventricular ﬁbrillation. The main
results are summarized in Figure 1.
The pCO2 and venous pH did not change after admin-
istration of theophylline (Figures 1(a) and 1(b)). The
baseline body temperatures of the MHS (37.5◦C (36.6–
38.6◦C)) and MHN swine (37.4◦C (35.8–37.8◦C)) as well as
lactate levels of 1.8mmol·L−1 (0.4–3.4mmol·L−1)i nM H S
and 1.8mmol·L−1 (0.8–6.5mmol·L−1) in MHN animals
remained unchanged. The HR of all swine increased at
cumulativedosesof93.5mg·kg−1 theophylline(Figure 1(c)),
while the MAP decreased. In MHS swine MAP decreased
from 84.5mmHg (60–104mmHg) to 65.5mmHg (48–
67mmHg) after administration of 93.5mg·kg−1 theo-
phylline.InMHNswinethedecreasewasmoremarked,from
84mmHg (67–98mmHg) to 53.5mmHg (50–68mmHg).
There were no diﬀerences in blood theophylline con-
centrations between MHS and MHN swine. A mean blood
concentration of 13.9mg·mL−1 (12.3–16.2mg·mL−1) theo-
phyllinewasfoundafter30minutesandacumulativedoseof
8.5mg·kg−1 (Figure 1(d)). These concentrations lie within
the therapeutic range for humans (8–20mg·kg−1). Ten
minutes after the last dose (93.5mg·kg−1) the mean blood
concentration was 122.4mg·mL−1 (99.3–154.4mg·mL−1).
4. Discussion
The cytoplasmic Ca2+ concentration is regulated by a vari-
ety of intracellular second-messenger systems. Alterations
in second-messenger systems, for example, the serotonin
system or inositol polyphosphates, have been found to be
associated with MH [2, 3]. The cAMP system also appearsJournal of Biomedicine and Biotechnology 3
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Figure 1: Central-venous pCO2 (a), central-venous pH (b), heart rate (c), and plasma theophylline concentration (d) following cumulative
intravenous administration of theophylline in malignant hyperthermia-susceptible (MHS) and normal (MHN) swine. Shown are median ±
range.
∗P < 0.05 MHS versus MHN;
†P < 0.05 MHS versus 0 minutes;
‡P < 0.05 MHN versus 0 minutes.
to be altered in MH [4–7]. Higher cytoplasmic cAMP
content and adenyl-cyclase activity have been found in MHS
compared to MHN patients. Additionally, serum cAMP
concentrations during and after physical exercise increased
moreandforlongertimeperiodsinMHScomparedtoMHN
patients [6]. One mode of action of methylxanthines is the
unspeciﬁc inhibition of PDEs, which leads to enhancement
of cytoplasmic cAMP. Furthermore, a MH-speciﬁc eﬀect of
the methylxanthine caﬀeine is well known and is used as a
gold standard in the IVCTs for the diagnosis of MH [10, 13].
There are several case reports describing patients who
developed MH-like symptoms without receiving the classic
trigger substances such as succinylcholine or volatile anes-
thetics [1]. However, MH symptoms are largely unspeciﬁc.
The clinical presentation of theophylline intoxication can
be very similar to MH, for example, with tachycardia,
hyperthermia, dehydration, convulsions, and coma as well
as skeletal-muscle cramps and rhabdomyolysis. In indi-
vidual cases, hypermetabolic theophylline overdoses have
been treated successfully with dantrolene [14]. Therefore,
a possible trigger mechanism of theophylline for MH was
suggested [15].
The MH trigger potential of methylxanthines has been
testedinseveralanimalstudies.AminophyllineinducedMH-
like symptoms in anesthetized rabbits, but a genetic basis
of MH susceptibility in these animals was not examined
in this study [16]. In MHS swine, i.v. and oral admin-
istration of caﬀeine potentiated the development of MH
crises induced by halothane and succinylcholine [17]. It was
therefore suggested that caﬀeine may reduce the threshold
of MH trigger agents. Furthermore, the detection of speciﬁc
in vitro eﬀects of theophylline in porcine skeletal-muscle
preparations supported the hypothesis of an MH trigger
potential for methylxanthines [11].
In this study, theophylline was not a trigger of MH in
susceptible swine. No signiﬁcant diﬀerences between MHS
and MHN swine or symptoms of hypermetabolism could
be found during cumulative administration of theophylline.
The therapeutic blood level of theophylline in humans is
estimated at between 8.0 and 20.0mg·mL−1. After cumu-
lative administration of 93.5mg theophylline, the swine in
our study died in hemodynamic decompensation. The mean
blood level measured at this time was 122.4mg·mL−1(99.3–
154.4mg·mL−1) or 0.68mmol·L−1 (0.55–0.86mmol·L−1)
theophylline. A direct comparison between in vivo blood
concentrations and concentrations in IVCTs is impossible.
However, in vitro contracture development in isolated
porcine MHS muscle specimens started at concentrations of
3.0mmol·L−1 theophylline.Therefore,itcouldbespeculated
that the in vivo theophylline concentrations in this study4 Journal of Biomedicine and Biotechnology
were high enough to kill the animals, but too low to trigger
MH.
Theophylline induces a sympathoadrenergic response
comparable with a strong stress reaction. Stress is a well-
known trigger of MH in swine, whereas the role of stress in
human MH is still unclear [9, 18]. Considering the results of
this study, theophylline might be a cofactor in the induction
of MH in humans, but does not appear to be a primary
trigger of MH.
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